Sign In

Kyle Landskroner

Head of Preclinical Drug Development at AZAFAROS B.V.

Kyle Landskroner is a seasoned professional with a diverse background in Research & Development, Pharma Portfolio and Project Management, Corporate Finance, M&A execution, and risk-adjusted financial valuations for drug development assets.

With expertise in leadership, project management, financial modeling, and strategic decision-making, Kyle has a strong track record in both small molecule and protein therapeutics across various disease states.

Having held key positions at reputable organizations like AZAFAROS B.V., Novartis International AG, Actelion Pharmaceuticals, and Bayer HealthCare, Kyle's experience ranges from early-stage discovery projects to post-marketing activities, showcasing a comprehensive understanding of the pharmaceutical industry.

His educational background includes a BS in Biochemistry from the University of Oregon and a PhD in Comparative Biomedical Science focusing on Pharmacology from North Carolina State University's College of Veterinary Medicine.

Kyle Landskroner has demonstrated proficiency in scientific areas such as hemostasis and thrombosis, PK/PD, and drug development, enhancing his ability to lead teams in complex projects and strategic initiatives.

His skill set includes financial modeling in Excel, portfolio analytics, risk assessment, and employing various analytical tools like sensitivity analyses, decision trees, and Monte Carlo simulations to drive informed decision-making.

Known for his strong interpersonal skills, problem-solving abilities, and effective presentation style, Kyle excels in both independent and collaborative settings in global environments.

Overall, Kyle Landskroner's extensive industry knowledge and leadership capabilities position him as a valuable asset in pharmaceutical Research & Development and strategic portfolio management.

Kyle Landskroner
Add to my network

Location

Basel Area, Switzerland